Key clinical point: Response and survival with current therapies remain poor in patients with atypical chronic myeloid leukemia (aCML), with allogeneic stem cell transplantation (allo-SCT) being the only treatment associated with improved survival.
Major finding: Overall response rate was 29%, with only 3 patients achieving a complete response. The median overall survival (OS) was 25 (95% confidence interval, 20.0-30.0) months, with OS being worst in patients receiving intensive chemotherapy than those receiving hypomethylating agents, ruxolitinib, or hydroxyurea. Allo-SCT was associated with improved survival (hazard ratio, 0.144; P = .007).
Study details: This retrospective study included 65 patients (median age, 67 years) with aCML.
Disclosures: This study was funded by grants from The University of Texas MD Anderson Cancer Center. Some investigators reported financial and/or nonfinancial ties with various pharmaceutical companies.
Source: Montalban-Bravo G et al. Cancer. 2021 Apr 29. doi: 10.1002/cncr.33622 .